31% delay in time to onset of confirmed disability progression in non-relapsing Secondary Progressive Multiple Sclerosis (SPMS) 20 September, 2024: Positive results from the HERCULES phase 3 study in people with non-relapsing secondary progressive multiple sclerosis (nrSPMS) demonstrated that tolebrutinib delayed the time to onset of 6-month confirmed disability progression (CDP) by 31% compared to…
Spinocerebellar ataxia – troriluzole topline results
Biohaven achieves positive results in pivotal study September 23 2024 Biohaven Ltd have announced positive topline results from pivotal Study BHV4157-206-RWE (NCT06529146) demonstrating the efficacy of troriluzole on the mean change from baseline in the f-SARA after 3 years of treatment. The study achieved the primary endpoint and showed statistically significant improvements on the f-SARA…
US launch of CREXONT® for Parkinson’s disease
23 September 2024: Amneal Pharmaceuticals has announced that it has launched CREXONT® (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease. CREXONT® is a novel, oral formulation of carbidopa/levodopa (CD/LD) that combines both immediate-release granules and extended-release pellets. “We are pleased to launch CREXONT and make it broadly available to healthcare providers and patients. The…
Rewriting the story of dementia
Poetry book challenges mainstream media portrayal In the palm of a spider’s hand by Gerald King, who was diagnosed with young-onset Alzheimer’s at 55, aims to challenge the dehumanising narratives about dementia perpetuated by mainstream media. This publication seeks to redefine how we understand and engage with the lived dementia experience. King’s words liken Alzheimer’s…
Deutetrabenazine for Tardive Dyskinesia
Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients 21st September 2024: Teva Pharmaceutical Industries Ltd has announced that a new analysis from the European cohort of the RIM-TD open-label extension (OLE) study revealed that deutetrabenazine treatment of patients with Tardive Dyskinesia (TD) was associated with long term improvement of TD symptoms….
Triptans effective for acute migraine sufferers
Study suggests Triptans are the most effective medicine for adults who experience acute migraines Findings of a study, in which researchers looked at 137 controlled trials that tested oral drugs commonly used to treat migraines, have been published in The British Medical Journal. The trials involved a total of 89,445 patients who were given one of 17…
Phase 1 study of UB-312 shows promise in Parkinson’s disease
In a study published in Nature Medicine on 18th September 2024, Parkinson’s patients reported improved daily movement with Vaxxinity’s Parkinson’s drug UB-312. The small trial, which included work from researchers at the University of Texas, the Mayo Clinic, and the Michael J. Fox Foundation for Parkinson’s Research, included only 20 people with Parkinson’s. However, it…
FDA clearance for amyloid imaging software in Alzheimer’s disease
GE HealthCare’s MIM Software division has received FDA clearance for software to image amyloid plaque in the brains of people with Alzheimer’s disease. The automated MIMneuro programme analyses PET images from any scanner using injectable tracer agents with the aim of providing a standardised metric for one of the main aspects of Alzheimer’s pathology. It…
FDA approves subcutaneous Ocrevus in the US
Ocrevus Zunovo is a twice yearly, under the skin treatment offered in clinic “This is something than can be provided in clinics and doesn’t require people to go to an infusion center,” David Jones, Genentech’s Medical Director for MS, said in an interview. “This will expand access to individuals who may not be able to…
